Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography

摘要: Inhibitors targeting the integrin alpha(v)beta(3) are promising new agents currently tested in clinical trials for supplemental therapy of glioblastoma multiforme (GBM). The aim our study was to evaluate (18)F-labeled glycosylated Arg-Gly-Asp peptide ([(18)F]Galacto-RGD) PET noninvasive imaging expression patients with GBM, suggesting eligibility this kind additional treatment. Patients suspected or recurrent GBM were examined [(18)F]Galacto-RGD PET. Standardized uptake values (SUVs) tumor hotspots, galea, and blood pool derived by region-of-interest analysis. images fused cranial MR image-guided surgery. Tumor samples taken from areas intense tracer accumulation analyzed histologically immunohistochemically expression. While normal brain tissue did not show significant (mean SUV, 0.09 +/- 0.04), GBMs demonstrated but heterogeneous uptake, a maximum highly proliferating infiltrating tumors 1.6 0.5). Immunohistochemical staining prominent microvessels as well glial cells. In cells, correlated immunohistochemical corresponding samples. These data suggest that [(18)F] Galacto-RGD successfully identifies might be tool planning monitoring individualized cancer therapies integrin.